Cubist Systematic Strategies LLC Invests $134,000 in Agenus Inc (AGEN)
Cubist Systematic Strategies LLC purchased a new stake in shares of Agenus Inc (NASDAQ:AGEN) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 30,488 shares of the biotechnology company’s stock, valued at approximately $134,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AGEN. Artal Group S.A. grew its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Agenus by 511.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 74,407 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in shares of Agenus by 12.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of Agenus during the 2nd quarter valued at $251,000. Hedge funds and other institutional investors own 37.87% of the company’s stock.
In related news, CEO Garo H. Armen bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average cost of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Karen Valentine sold 8,358 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the transaction, the insider now owns 109,879 shares of the company’s stock, valued at $380,181.34. The disclosure for this sale can be found here. Insiders sold 20,514 shares of company stock valued at $70,978 over the last quarter. 7.60% of the stock is owned by company insiders.
Agenus Inc (NASDAQ:AGEN) opened at $3.87 on Friday. The company has a market cap of $336.69, a price-to-earnings ratio of -3.31 and a beta of 2.11. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus Inc has a 1 year low of $3.20 and a 1 year high of $5.45.
Agenus (NASDAQ:AGEN) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $5.91 million. The company’s revenue was down 24.4% compared to the same quarter last year. sell-side analysts anticipate that Agenus Inc will post -1.16 earnings per share for the current fiscal year.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.